Psoriasis Through a Systems Lens

Psoriasis is often thought of as a skin condition. It is better understood as a systemic inflammatory disease that is most visible in the skin. It affects around 2 to 3 percent of people in many populations, often begins in early adulthood, and carries associations with joint disease, cardiovascular and metabolic disease, bowel inflammation and mental health problems. A systems view helps practitioners support patients beyond the skin, while dermatological treatment remains central.

What drives psoriasis

Psoriasis arises from an interaction between genetic susceptibility and immune activation. Dendritic cells in the skin produce interleukin 23, which drives T helper 17 cells to release interleukin 17 and other cytokines. These cause skin cells to proliferate rapidly and attract more immune cells, creating the characteristic thickened, scaly plaques. Treatments that block interleukin 17, interleukin 23 or tumour necrosis factor are highly effective, confirming the central role of these pathways.

Triggers and mediators

Associated conditions

• Psoriatic arthritis: affects a substantial minority of people with psoriasis, often years after skin disease begins. Early recognition and treatment prevent joint damage.
• Cardiometabolic disease: psoriasis, particularly when severe, is associated with obesity, metabolic syndrome, type 2 diabetes, dyslipidaemia, hypertension and cardiovascular disease.
• Fatty liver disease: more common in psoriasis and relevant to some treatments such as methotrexate.
• Inflammatory bowel disease: more common, particularly Crohn disease.
• Depression and anxiety: common, affected by visible disease and stigma, and associated with inflammation.
• Uveitis and other inflammatory conditions.

What the evidence says about lifestyle

Weight loss

In a randomised trial in people with psoriasis and obesity, a low energy diet leading to weight loss improved psoriasis severity and quality of life compared with a control diet. Weight loss also improves response to some systemic treatments and reduces cardiometabolic risk. For people with obesity, supporting weight loss is one of the most evidence based adjuncts to dermatological care.

Dietary pattern

In a large observational study, higher adherence to a Mediterranean diet was associated with less severe psoriasis. Trial evidence for specific diets beyond weight loss is limited. Guidance from psoriasis organisations supports dietary weight reduction for people with overweight and suggests a Mediterranean style pattern may be reasonable.

Gluten

People with psoriasis have an increased likelihood of coeliac disease. A gluten free diet may improve psoriasis in people who have coeliac disease or coeliac antibodies, based on small studies. For others, evidence of benefit is lacking.

Alcohol and smoking

Reducing alcohol and stopping smoking are recommended; both are associated with more severe disease, and alcohol is particularly relevant with methotrexate.

Supplements

Oral vitamin D and fish oil have shown inconsistent results in trials and are not established treatments for psoriasis, although correcting deficiency is reasonable. Topical vitamin D analogues are established treatments, a different matter from oral supplements.

Stress

Psychological interventions, including cognitive behavioural approaches, may help some people cope with psoriasis and may reduce severity, though evidence is limited.

Screening and coordination

1. Ask about joints: pain, swelling, morning stiffness, swollen fingers or toes, heel pain, back pain. Validated screening questionnaires can help identify people who need rheumatology assessment.
2. Assess cardiometabolic risk: weight, waist, blood pressure, lipids, glucose, liver tests.
3. Ask about bowel symptoms and consider calprotectin where indicated.
4. Screen for depression and anxiety.
5. Consider coeliac serology where symptoms or deficiencies suggest it.
6. Review medicines that may worsen psoriasis, with the prescriber.
7. Coordinate with dermatology on treatment choices, particularly where lifestyle factors affect treatment safety or response.

An illustrative case

A 45 year old man has moderate plaque psoriasis that has worsened over 2 years, alongside weight gain of 15 kg, heavy weekend drinking and heel and finger pain. He is taking a beta blocker for anxiety related palpitations. His blood tests show raised triglycerides, prediabetes and a raised ALT.

His practitioner recognises possible psoriatic arthritis and arranges rheumatology referral, where the diagnosis is confirmed and treatment started that addresses both skin and joints. His doctor reviews the beta blocker and switches to an alternative. A structured weight management plan with a dietitian, reduced alcohol and a gradual activity programme follow. At 6 months he has lost 9 kg, his psoriasis has improved substantially with treatment and lifestyle change, his joint pain has settled and his liver tests and glucose have improved.

More than skin

Psoriasis illustrates why a systems view matters. Effective dermatological treatment is essential, but so is recognising the joints, metabolism, liver, gut and mind, and addressing the lifestyle factors that influence both the disease and its associated risks.